Lesson plan
Lu AF35700
Lu AF35700, also known as d8-zicronapine, is an experimental antipsychotic which was under development for the treatment of schizophrenia and schizoaffective disorder but was never marketed. It is taken orally. The drug is a non-selective dopamine receptor antagonist, including of the dopamine D 1 , D 2 , D 3 , D 4 , and D 5 receptors (K i = 0.56 nM, 4.1 nM, 16 nM, 6.8 nM, and 0.37 nM, respectively). In addition, it is an antagonist of the serotonin 5-HT 2A , 5-HT 2B , 5-HT 2C , and 5-HT 6 receptors (K i = 0.96 nM, 0.4 nM, 1.5 nM, and 0.59 nM, respectively). The drug also shows affinity for and acts as an antagonist of various adrenergic receptors. It is not an antagonist of the muscarinic acetylcholine receptors, but does show high affinity for the histamine H 1 receptor (K i = 4 nM). Lu AF35700 is unusual among antipsychotics in that it shows marked and in fact preferential blockade of the dopamine D 1 -like receptors in addition to the dopamine D 2 -like receptors. This has conferred it with unique preclinical pharmacological effects and potential therapeutic benefits. The drug is an octadeuterated isotopologue of zicronapine (Lu 31-130). Lu AF36152 is the N-desmethyl active metabolite of Lu AF35700. Lu AF35700 was under development by Lundbeck A/S.…
Article summary
Lu AF35700, also known as d8-zicronapine, is an experimental antipsychotic which was under development for the treatment of schizophrenia and schizoaffective disorder but was never marketed. It is taken orally. The drug is a non-selective dopamine receptor antagonist, including of the dopamine D 1 , D 2 , D 3 , D 4 , and D 5 receptors (K i = 0.56 nM, 4.1 nM, 16 nM, 6.8 nM, and 0.37 nM, respectively). In addition, it is an antagonist of the serotonin 5-HT 2A , 5-HT 2B , 5-HT 2C , and 5-HT 6 receptors (K i = 0.96 nM, 0.4 nM, 1.5 nM, and 0.59 nM, respectively). The drug also shows affinity for and acts as an antagonist of various adrenergic receptors. It is not an antagonist of the muscarinic acetylcholine receptors, but does show high affinity for the histamine H 1 receptor (K i = 4 nM). Lu AF35700 is unusual among antipsychotics in that it shows marked and in fact preferential blockade of the dopamine D 1 -like receptors in addition to the dopamine D 2 -like receptors. This has conferred it with unique preclinical pharmacological effects and potential therapeutic benefits. The drug is an octadeuterated isotopologue of zicronapine (Lu 31-130). Lu AF36152 is the N-desmethyl active metabolite of Lu AF35700. Lu AF35700 was under development by Lundbeck A/S.…
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.